[1]徐霜霜,曹 响,赵 洁,等.益肾泄浊活血法改善非透析慢性肾脏病患者微炎症状态的 meta 分析[J].大众科技,2019,21(09):78-82.
　Meta-Analysis of Tonify Kidney, Drain Turbidity and Blood-Activating Therapy forMicroinflammation in Non-dialysis Patients with Chronic Kidney Disease[J].Popular Science & Technology,2019,21(09):78-82.
点击复制

益肾泄浊活血法改善非透析慢性肾脏病患者微炎症状态的 meta 分析()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
21
期数:
2019年09
页码:
78-82
栏目:
医药与卫生
出版日期:
2019-09-20

文章信息/Info

Title:
Meta-Analysis of Tonify Kidney, Drain Turbidity and Blood-Activating Therapy forMicroinflammation in Non-dialysis Patients with Chronic Kidney Disease
作者:
徐霜霜;  曹 响;  赵 洁;  刘吉尧;  谢丽萍
（广西中医药大学第一附属医院，广西 南宁 530023）
关键词:
益肾泄浊活血法; 慢性肾脏病; 微炎症; meta 分析
Keywords:
tonify kidney;  drain turbidity and blood-activating therapy;  chronic kidney disease;  microinflammation;  meta-analysis
文献标志码:
A
摘要:
目的：为益肾泄浊活血法改善非透析慢性肾脏病患者微炎症状态的疗效性提供客观证据，探索改善慢性肾脏病微炎症状态的中医药治法。方法：检索在知网、万方、维普、中国生物医学文献数据库、Pub Med、EMBASE 上公开发表的随机临床对照研究文献，根据纳入和排除标准对文献进行筛选，参考 Cochrane 系统评价员手册对最终纳入文献进行质量评价，提取数据后用 RevMan 5.1 进行 Meta 分析。结果：（1）14 篇文献的 1217 例患者纳入本项研究，其中对照组 615 例，治疗组 602例。对照组予西医一般基础治疗，治疗组在西医一般治疗基础上加用符合益肾泄浊活血治法的中药组方治疗，给药方式为口服给药。（2）meta 分析结果表明，治疗组患者的微炎症状态低于对照组，hs-CRP、白介素 6 和肿瘤坏死因子 α 差异有统计学意义P＜0.00001。结论：益肾泄浊活血法对非透析慢性肾脏病患者微炎症状态的改善有较好的作用，可减缓慢性肾脏病患者进入透析阶段的进程，但目前相关临床研究缺少大样本、多中心的研究，质量较低，用益肾泄浊活血法治疗非透析慢性肾脏病患者微炎症反应的疗效性及安全性还需进一步研究。
Abstract:
Objective: To evaluate the clinical effectiveness and providing objective evidence of tonify kidney, drain turbidity andblood-activating therapy for microinflammation in non-dialysis patients with chronic kidney disease (CKD). Method: The studiespublished on HowNet, Wanfang, Weipu, China Biomedical Literature Database, Pub Med and EMBASE were retrieved. The literatureswere screened according to inclusion and exclusion criteria. The final included literatures were evaluated by referring to the Cochranesystem evaluator’s manual. The Meta-analysis of the data extracted was performed by RevMan 5.1 software. Results: (1) Fourteen pieces ofliterature including 1217 people were brought into the meta-analysis. The control group was treated with general basic treatment of Westernmedicine, while the treatment group was treated with traditional Chinese medicine prescriptions which accorded with the treatment oftonify kidney, drain turbidity and blood-activating therapy on the basis of general treatment of Western medicine. (2) The results ofmeta-analysis showed that the microinflammation status in the treatment group was lower than that in the control group, and the differencesof hs-CRP, IL-6 and TNF-α were statistically significant (P ＜ 0.00001). Conclusion: The method of tonify kidney, drain turbidity andblood-activating therapy has a better effect on improving microinflammation of non-dialysis patients with CKD, and can slow down theprocess of CKD patients entering dialysis stage. However, at present, there is a lack of large sample and multi-center research in relevantclinical studies, and the quality is low. The efficacy and safety of the therapy in treating microinflammation in non-dialysis patients withCDK need further study.

参考文献/References:

[1] 张路霞,王梅,王海燕.慢性肾脏病的流行病学研究[J].中华肾脏病杂志,2005(7):425-428.[2] 沈文清,邢艳芳,黄丽,等.微炎症及氧化应激对慢性肾脏病患者肾功能的影响[J].中国临床医学,2012,19(5):500-501.[3] Stenvinkel P. Strong association between malnutrition,inflammation, and atherosclerosis in chronic renalfailure[J]. Kidney Int,1999,55:1899-1911.[4] 魏明刚.肾病微炎症状态的中医理论探讨[J].中医杂志,2011,52(10):813-815.[5] 邓丽娥,何世东.何氏养肾方对慢性肾脏病患者炎症指标的影响[J].中医临床研究,2017,9(33):104-105.[6] 郜枫,黄飞.康肾汤对慢性肾脏病 2~3 期患者微炎症状态的影响研究[J].现代中西医结合杂志,2015,24(25):2747-2749.[7] 吴锋,孙悦,张彤,周庆华,何立群.健脾清化方对 CKD2～3期患者慢性微炎症状态的随机对照多中心研究[J].中国中西医结合肾病杂志,2012,13(6):504-506.[8] 赖丽金.加减温胆汤对慢性肾脏病 3 期微炎症状态的临床观察[D].广州:广州中医药大学,2015.[9] 陈彩凤.益肾降浊冲剂对 CKD3、4 期患者骨代谢指标及白介素-17 的影响[D].福建:福建中医药大学,2012.[10] 范伟,胡路,柳志猛,等.益肾活血利湿解毒法对 CKD3-4 期患者微炎症状态影响的临床研究[J].时珍国医国药,2018,29(7):1669-1672.[11] 郑剑琴,王晓光.补脾益肾活血泻浊法对慢性肾脏病微炎症状态改善临床观察[J].实用中西医结合临床,2018,18(6):18-19.[12] 杨婧,严睿俊,王琛,等.肾衰Ⅱ号方对慢性肾脏病患者肾功能及炎症因子的影响[J].中国中医药信息杂志,2014,21(12):15-18.[13] 包娅琼.益气活血通络方对慢性肾脏病 3 期、4 期气虚血瘀证患者的临床观察—血清 PTX3、LP(a)、hs-CRP 的影响[D].合肥:安徽中医药大学,2015.[14] 伍劲华.肾衰合剂对慢性肾衰整体功能代偿及微炎症状态的影响[J].新中医,2007,39(7):84-85.[15] 张均,赵景宏,刘力,等.健脾益肾泄浊方联合西医治疗慢性肾衰竭对患者免疫功能及微炎症状态的影响[J].现代中西医结合杂志,2017,26(35):3906-3908.[16] 温旭,杨秀炜,赵涛,等.肾衰方对慢性肾衰竭患者血清微炎症状态的影响及肾功能保护作用[J].长春中医药大学学报,2018,34(2):302-305.[17] 杜浩昌,陈英兰,周健淞.培本祛瘀冲剂对脾肾虚衰、湿浊瘀阻型慢性肾衰患者肾功能和微炎症状态的影响[J].中国实验方剂学杂志,2012,18(1):234-236.[18] 成晓萍,于小勇,程小红,等.益血降浊汤对慢性肾脏病 4 期微炎症状态的影响[J].陕西中医,2015,36(4):399-401.[19] Kaysen G A. The microinflammatory state in uremia: causesand potential consequences[J]. American Society ofNephrology. Journal, 2001,12(7):1549-1557.[20] 王佳玉,李建英.慢性肾衰竭微炎症状态与肾性贫血研究hemodialysis [J]. Medicina,2011,71(1):66-72.[21] 罗佳佳,褚以德,李瑜琳.慢性肾脏病微炎症状态及其与营养不良关系的研究进展[J].山东医药,2016,56(14):107-109.[22] Young P, Lombi F, Finn BC, et al. Malnutrition-inflammation complex syndrome in chronic AmericanSociety of Nephrology[J]. 2001,12(7):1549-1557.[23] 杨水金,蒋更如,刘爽,等.血清超敏 C 反应蛋白水平与慢性肾脏病患者心血管并发症发生风险关系的探讨[J].现代生物医学进展,2018,18(15):2873-2877.[24] 郑智华,马祖等,郝元涛,等.持续性非卧床腹膜透析患者生存质量影响因素的研究[J].中华肾脏病杂志,2005,21(5):290-294.[25] 丁英钧,蔡冀民,潘莉,等.慢性肾脏病“肾络淤阻”共有病机学说及临床意义[J].时珍国医国药,2011,22(3):690-691.[26] 高坤,孙伟,周栋,等.慢性肾脏病中医证型分布及演变规律研究[J].江苏中医药,2008,40(6):33-35.[27] 周海波,晏子友.以肾虚浊伏为核心探析慢性肾衰病病机[J].四川中医,2019,37(3):31-34.[28] 朱辟疆,周逊,赵华,等.慢性肾功能衰竭微炎症状态与中医证型关系研究[J].现代中西医结合杂志,2008(5):652-654.[29] 祝亮,鲁庆红,王志芳,等.尿毒清颗粒对早中期慢性肾衰竭微炎症状态的作用[J].中华中医药学刊,2018,36(6):1474-1477.[30] Sarmad Sheraz Jadoon,丁莉,张舜波,等.补虚药的药理学研究思路与方法[J].中国医药导报,2018,15(10):114-117.[31] 邢增智,陈旺,曾宇.泽泻的化学成分与药理作用研究进展[J].中医药导报,2017,23(15):75-78.[32] 高樱,杨龙飞,翟阳,等.具有活血化瘀功效的中药药理作用及机制研究进展[J].中华中医药杂志,2018,33(11):5053-5056.[33] 梁莹,王妍春.慢性肾脏病微炎症状态的诊断与治疗[J].实用医学杂志,2016,32(7):1186-1188.

相似文献/References:

[1]唐 张.尿毒清颗粒对慢性肾脏病 3～4 期患者微炎症状态的影响[J].大众科技,2019,21(09):44.
　Effect of Niaoduqing Granule on Microinflammation in Patients with Stage 3-4Chronic Kidney Disease[J].Popular Science & Technology,2019,21(09):44.
[2]胡 雯.中医药治疗慢性肾脏病睡眠障碍的研究进展[J].大众科技,2019,21(05):97.
　Research Progress on Sleep Disorder of Chronic Kidney Disease Treated byTraditional Chinese Medicine[J].Popular Science & Technology,2019,21(09):97.
[3]刘威利　向少伟 韦海敏　钟文露　任倩倩.慢性肾脏病血管钙化中西医治疗研究进展[J].大众科技,2020,22(11):100.
　Research Progress of Traditional Chinese and Western Medicine in the Treatment of Vascular Calcification in Chronic Kidney Disease[J].Popular Science & Technology,2020,22(09):100.
[4]吴铁雄　刘旭东　朱沪敏　黄 露　李品桦 庞华珍.非酒精性脂肪性肝病对肾功能指标影响的研究进展[J].大众科技,2021,23(6):63.
　Research Progress on the Influence of Non-alcoholic Fatty Liver Disease on Renal Function Index[J].Popular Science & Technology,2021,23(09):63.
[5]黄源铭 杨 浩 陈金娜 谢丽萍.积雪草的作用机制及临床应用现状[J].大众科技,2022,24(11):92.
　Action Mechanism and Clinical Application Status of Centella Asiatica[J].Popular Science & Technology,2022,24(09):92.

备注/Memo

备注/Memo:
【收稿日期】2019-07-05【作者简介】徐霜霜（1993－），女，广西中医药大学在读硕士研究生，研究方向为中医药防治慢性肾脏病。
更新日期/Last Update: 2020-01-23